National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 5) (Cth)
PB 62 of 2021
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 5)
National Health Act 1953
___________________________________________________________________________
I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under paragraph 98C(1) of the National Health Act 1953.
Dated 29 June 2021
NIKOLAI TSYGANOV
Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
___________________________________________________________________________
Name of Instrument
(1)This Instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 5).
(2)This Instrument may also be cited as PB 62 of 2021.
Commencement
This Instrument commences on 1 July 2021.
Amendments to National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019
Schedule 1 amends the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019.
Schedule 1 Amendments
Schedule 3, after entry for Hydromorphone in the form Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 200 mL
insert:
| Hydromorphone | Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL |
0
0
0